ArticleScience advances2022
Complement C3 inhibition in severe COVID-19 using compstatin AMY-101.
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
5.1field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 53 citations in OpenAlex.
- In vivo evidence of effective complement modulation by TriFu in comparison to C5 inhibition and complement depletion.Blood advances · 2026Article
- New Analogs of the Compstatin Family of Clinical Complement Inhibitors with Low Picomolar Target Affinity.Journal of medicinal chemistry · 2026Article
- The Complement System in the Setting of Critical Illness-A Narrative Review.Biomolecules · 2026Review
- Complement Hyperactivation Is Mediated by Alternative and Lectin Pathways During Early Phase of Severe Vaccination-Omicron BA.5 Infection.Journal of medical virology · 2026Article
- Investigation into the Pancreatic Pathogenesis of SFTSV across Multiple Levels.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Engineered Dual-Function Antibody-Like Proteins to Combat SARS-CoV-2-Induced Immune Dysregulation and Inflammation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Clinical C3 Inhibition With AMY-101 Reveals Novel Insights Into IL-8-Driven Inflammation in COVID-19.Immunology · 2025Article
- Knowing the enemy: strategic targeting of complement to treat Alzheimer disease.Nature reviews. Neurology · 2025Review
- 'Complement-ing' tissue inflammation via granzyme K?Nature immunology · 2025Article
- Emerging Targets, Novel Directions, and Innovative Approaches in Thrombosis Therapy.Aging and disease · 2025Review
- Pneumonia: Recent Updates on Diagnosis and Treatment.Microorganisms · 2025Review
- The endothelial-immunothrombotic storm in viral sepsis: lessons from COVID-19.Frontiers in immunology · 2025Review
- Proteomic analysis of lung responses to SARS-CoV-2 infection in aged non-human primates: clinical and research relevance.GeroScience · 2024Article
- Complement-targeted therapeutics: Are we there yet, or just getting started?European journal of immunology · 2024Review
- Complement system activation: bridging physiology, pathophysiology, and therapy.Intensive care medicine · 2024Review
- The complement system: A key player in the host response to infections.European journal of immunology · 2024Review
- Enhanced complement activation and MAC formation accelerates severe COVID-19.Cellular and molecular life sciences : CMLS · 2024Article
- Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways.The Journal of biological chemistry · 2024Article
- Control of complement-induced inflammatory responses to SARS-CoV-2 infection by anti-SARS-CoV-2 antibodies.The EMBO journal · 2024Article
- Emerging role of complement in COVID-19 and other respiratory virus diseases.Cellular and molecular life sciences : CMLS · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 13 institutions in 7 countries.
Panagiotis SkendrosFirst Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.ORCID 0000-0003-0456-7015
Georgios GermanidisFirst Department of Internal Medicine, AHEPA University Hospital, and Basic and Translational Research Unit, Special Unit for Biomedical Research and Education (SUBRE), School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID 0000-0001-7985-3118
Dimitrios C MastellosNational Center for Scientific Research "Demokritos", Athens, Greece.ORCID 0000-0002-6634-3271
Christina AntoniadouFirst Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.ORCID 0000-0001-7391-6851
Efstratios GavriilidisFirst Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.ORCID 0000-0002-1591-9760
Georgios KalopitasFirst Department of Internal Medicine, AHEPA University Hospital, and Basic and Translational Research Unit, Special Unit for Biomedical Research and Education (SUBRE), School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID 0000-0002-4962-790X
Anna SamakidouDepartment of Medicine and Research Laboratory of Internal Medicine, National and European Expertise Center of Greece in Autoimmune Liver Diseases (ERN Rare-Liver), General University Hospital of Larissa, Larissa, Greece.
Angelos LiontosDepartment of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.ORCID 0000-0002-0361-0846
Akrivi ChrysanthopoulouFirst Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.
Maria NtinopoulouFirst Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.
Dionysios KogiasFirst Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.ORCID 0000-0002-2505-7076
Ioanna KaranikaFirst Department of Internal Medicine, AHEPA University Hospital, and Basic and Translational Research Unit, Special Unit for Biomedical Research and Education (SUBRE), School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Andreas SmyrlisFirst Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.ORCID 0000-0002-3964-5944
Dainora CepaityteFirst Department of Internal Medicine, AHEPA University Hospital, and Basic and Translational Research Unit, Special Unit for Biomedical Research and Education (SUBRE), School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID 0000-0003-2652-4120
Iliana FotiadouFirst Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.ORCID 0000-0002-7618-4243
Nikoleta ZiogaFirst Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.ORCID 0000-0002-8614-6742
Ioannis MitroulisFirst Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.
Nikolaos K GatselisDepartment of Medicine and Research Laboratory of Internal Medicine, National and European Expertise Center of Greece in Autoimmune Liver Diseases (ERN Rare-Liver), General University Hospital of Larissa, Larissa, Greece.ORCID 0000-0002-3715-8640
Charalampos PapagorasFirst Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.ORCID 0000-0001-6207-496X
Simeon MetallidisFirst Department of Internal Medicine, AHEPA University Hospital, and Basic and Translational Research Unit, Special Unit for Biomedical Research and Education (SUBRE), School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Haralampos MilionisDepartment of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.ORCID 0000-0003-3958-2266
George N DalekosDepartment of Medicine and Research Laboratory of Internal Medicine, National and European Expertise Center of Greece in Autoimmune Liver Diseases (ERN Rare-Liver), General University Hospital of Larissa, Larissa, Greece.ORCID 0000-0001-7075-8464
Loek WillemsR&D Department, Hycult Biotechnology, Uden, Netherlands.
Barbro PerssonDepartment of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Vivek Anand ManivelDepartment of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-6746-7372
Bo NilssonDepartment of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden.
E Sander ConnollyDepartment of Neurological Surgery, Columbia University, New York, NY, USA.
Simona IacobelliDepartment of Biology, University of Rome Tor Vergata, Rome, Italy.
Vasileios PapadopoulosFirst Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.ORCID 0000-0002-4188-9518
Rodrigo T CaladoDepartment of Medical Imaging, Hematology and Oncology, University of São Paulo, School of Medicine, Ribeirão Preto, Brazil.ORCID 0000-0002-7966-6029
Markus Huber-LangInstitute for Clinical and Experimental Trauma-Immunology, Ulm University Hospital, Ulm, Germany.ORCID 0000-0003-2359-6516
Antonio M RisitanoAORN Moscati Avellino, Italy and Federico II University of Naples, Naples, Italy.
Despina YancopoulouAmyndas Pharmaceuticals, Glyfada, Greece.
Konstantinos RitisFirst Department of Internal Medicine and Laboratory of Molecular Hematology, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.
John D LambrisDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.ORCID 0000-0002-9370-5776
Democritus University of Thrace · GRAHEPA University Hospital · GRUniversity Hospital of Larissa · GRUppsala University · SEUniversity of Ioannina · GRAzienda Ospedaliera S.Giuseppe Moscati · ITHycult Biotech (Netherlands) · NLNational Centre of Scientific Research "Demokritos" · GRNeurological Surgery · USUniversidade de São Paulo · BRUniversity Hospital Ulm · DEUniversity of Pennsylvania · USUniversity of Rome Tor Vergata · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complement C3 activation contributes to COVID-19 pathology, and C3 targeting has emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first randomized trial evaluating a C3 inhibitor, AMY-101, in severe COVID-19 (PaO2/FiO2 ≤ 300 mmHg). Patients received AMY-101 (
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.